AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...

AstraZeneca has struck a deal to acquire biotechnology company EsoBiotec for up to $1bn, as the London-listed pharmaceutical ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...

Macmillan Cancer Support and AstraZeneca are working in partnership on a new research project to understand the barriers ...